The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01970800
Recruitment Status : Unknown
Verified October 2013 by Maimonides Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : October 28, 2013
Last Update Posted : October 28, 2013
Information provided by (Responsible Party):
Maimonides Medical Center

Brief Summary:
The purpose of the study is to evaluate the predictive value of IGF-1 generation test for growth velocity during GH treatment for 12 months.

Condition or disease Intervention/treatment Phase
Short Stature Drug: Growth Hormone Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature
Study Start Date : January 2013
Estimated Primary Completion Date : January 2014
Estimated Study Completion Date : January 2014

Arm Intervention/treatment
Experimental: Growth hormone, injections
Growth hormone injection 0.3mg/kg/week dailY
Drug: Growth Hormone
Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
Other Name: Nutropin AQ

Primary Outcome Measures :
  1. Primary Efficacy Outcome measurement [ Time Frame: one year ]
    Growth velocity after treatment with appropriate growth hormone doses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • ability to provide written informed consent
  • Prepubertal males and females form 5- 11years old
  • Bone age <11 years in males and <9 years in females
  • Height SD score<-2.25SD in males and females
  • IGF-1SD score <-1SD in both males and females
  • Peak GH level after stimulation >10ng/ml

Exclusion Criteria:

  • History of prior chemotherapy and or radiation
  • Active neoplasm
  • Pediatric patients with closed epiphyses
  • Prader-Willi syndrome, Turner syndrome or any other genetic or chromosomal anomaly
  • Treatment with inhaled or systemic steroids
  • BMI <5th percentile or >95th percentile
  • Tanner 2 at clinical or biochemical examination by ultrasensitive LH and FSH

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01970800

Contact: Svetlana Ten, MD 718-283-8894

United States, New York
Maimonides Medical Center Not yet recruiting
Brooklyn, New York, United States, 11219
Sponsors and Collaborators
Maimonides Medical Center
Principal Investigator: Svetlana Ten, MD Maimonides Medical Center

Responsible Party: Maimonides Medical Center Identifier: NCT01970800     History of Changes
Other Study ID Numbers: 10/01/VA03
First Posted: October 28, 2013    Key Record Dates
Last Update Posted: October 28, 2013
Last Verified: October 2013

Keywords provided by Maimonides Medical Center:
Short Stature

Additional relevant MeSH terms:
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs